Tiba Biotech
Preclinical-stage biopharmaceutical company developing next-generation RNA medicines. Technology focus includes a biodegradable dendrimer-based nanoparticle platform for nucleic-acid delivery and computational RNA design to enable organ-targeted vaccines and therapeutics. Work includes preclinical vaccine and therapeutic programs, government-funded contracts and collaborations with academic and public-sector partners.
Industries
Nr. of Employees
small (1-50)
Patents
Nanoparticle compositions containing sugar functionalized nucleic acid carriers
US-12410448-B2
View DetailsNanoparticle compositions containing sugar functionalized nucleic acid carriers
US-11859201-B2
View Details
Nanoparticle compositions containing sugar functionalized nucleic acid carriers
US-12410448-B2
View DetailsNanoparticle compositions containing sugar functionalized nucleic acid carriers
US-11859201-B2
View DetailsProducts
Nanoparticle RNA delivery platform
A dendrimer-derived biodegradable nanoparticle platform for encapsulation and organ-directed delivery of RNA payloads intended to enable potent expression with reduced inflammatory response and reduced liver uptake.
Biodegradable Nanoparticles
Compact multilamellar structures approximately 100-150nm in diameter, utilizing fully synthetic biodegradable nanoparticles that overcome the limitations of traditional lipid nanoparticles.
Biodegradable Nanoparticle Delivery Platform
Fully biodegradable nanoparticle delivery platform designed for safer RNA vaccines and therapeutics.
Tiba RNA Design Platform
A computational and combinatoric approach to RNA design utilizing biodegradable nanoparticles with high payload capacity to deliver sophisticated biological functions and complex data structures to cells.
mRNA platform
Core mRNA delivery and vaccine platform developed from research at M.I.T. and the Whitehead Institute.
Nanoparticle RNA delivery platform
A dendrimer-derived biodegradable nanoparticle platform for encapsulation and organ-directed delivery of RNA payloads intended to enable potent expression with reduced inflammatory response and reduced liver uptake.
Biodegradable Nanoparticles
Compact multilamellar structures approximately 100-150nm in diameter, utilizing fully synthetic biodegradable nanoparticles that overcome the limitations of traditional lipid nanoparticles.
Biodegradable Nanoparticle Delivery Platform
Fully biodegradable nanoparticle delivery platform designed for safer RNA vaccines and therapeutics.
Tiba RNA Design Platform
A computational and combinatoric approach to RNA design utilizing biodegradable nanoparticles with high payload capacity to deliver sophisticated biological functions and complex data structures to cells.
mRNA platform
Core mRNA delivery and vaccine platform developed from research at M.I.T. and the Whitehead Institute.
Services
Collaborative programs to advance RNA vaccine and therapeutic candidates through preclinical evaluation, including antigen characterization and in vivo efficacy testing.
Collaborative programs to advance RNA vaccine and therapeutic candidates through preclinical evaluation, including antigen characterization and in vivo efficacy testing.
Expertise Areas
- Nucleic-acid delivery platform development
- RNA vaccine design (mRNA and self-amplifying RNA)
- Preclinical immunology and animal challenge studies
- Computational RNA sequence optimization
Key Technologies
- Dendrimer-based biodegradable nanoparticles
- Self-amplifying RNA (saRNA/esaRNA)
- Messenger RNA (mRNA) vaccines
- Small interfering RNA (siRNA) therapeutics
News & Updates
Awarded $749,999 through BARDA FASTx to develop a lung-directed nucleic-acid delivery platform for siRNA antivirals.
EZ-BAA contract to develop an RNAi-based therapeutic for H1N1 influenza delivered via a nanoparticle delivery platform (contract amount $749,999 reported).
Received a $400,000 SBIR Phase I award to develop spleen-targeted enhanced self-amplifying RNA payloads in combination with targeted delivery.
International challenge trials reported complete protection in cattle with an RNA vaccine candidate for foot-and-mouth disease.
Multi-year collaboration with a process-development and GMP-capable center to advance RNA vaccines for high-impact livestock diseases.
Selected to participate in a joint initiative to accelerate solutions for public health threats.
Awarded $749,999 through BARDA FASTx to develop a lung-directed nucleic-acid delivery platform for siRNA antivirals.
EZ-BAA contract to develop an RNAi-based therapeutic for H1N1 influenza delivered via a nanoparticle delivery platform (contract amount $749,999 reported).
Received a $400,000 SBIR Phase I award to develop spleen-targeted enhanced self-amplifying RNA payloads in combination with targeted delivery.
International challenge trials reported complete protection in cattle with an RNA vaccine candidate for foot-and-mouth disease.
Multi-year collaboration with a process-development and GMP-capable center to advance RNA vaccines for high-impact livestock diseases.
Selected to participate in a joint initiative to accelerate solutions for public health threats.